Experienced in Barrett Esophagus

Hubert Piessevaux

Cliniques Universitaires Saint Luc
Brussels, BRU, BE 
Experienced in Barrett Esophagus
Cliniques Universitaires Saint Luc
Brussels, BRU, BE 
OverviewLocationsClinical Research

Overview

Hubert Piessevaux practices in Brussels, Belgium. Mr. Piessevaux is rated as an Experienced expert by MediFind in the treatment of Barrett Esophagus. His top areas of expertise are Irritable Bowel Syndrome (IBS), Colorectal Cancer, Plasmacytoma, Endoscopy, and Pancreaticoduodenectomy.

His clinical research consists of co-authoring 79 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Barrett Esophagus.

Gender
Male

Locations

Cliniques universitaires Saint Luc
Brussels, BRU, Belgium
Other Locations
Leuven, VLG, Belgium

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Randomized, Sham and Cross-Over-Controlled Trial of Per-oral Endoscopic Pyloromyotomy (G-POEM) in Patients With Refractory Gastroparesis
A Randomized, Sham and Cross-Over-Controlled Trial of Per-oral Endoscopic Pyloromyotomy (G-POEM) in Patients With Refractory Gastroparesis
Enrollment Status: Completed
Publish Date: January 27, 2021
Intervention Type: Procedure
Study Phase: Not Applicable
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
A Phase II, Multicentre, Randomised, Double-blind, Placebo Controlled, Proof of Concept Study of Efficacy and Safety of Rifamycin SV-MMX® 600 mg Tablets Administered Three or Two Times Daily to Patients With Diarrhoea-predominant Irritable Bowel Syndrome (IBS-D)
Enrollment Status: Completed
Publish Date: January 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

79 Total Publications

Fermentable Oligo-Di-Mono-saccharides And Polyols (FODMAP) consumption in Belgian healthy adults and irritable bowel syndrome patients.
Fermentable Oligo-Di-Mono-saccharides And Polyols (FODMAP) consumption in Belgian healthy adults and irritable bowel syndrome patients.
Journal: Acta gastro-enterologica Belgica
Published: October 13, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Piessevaux's expertise for a condition
ConditionClose
      View All 20 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile